51 – 60 of 151
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
(
- Contribution to journal › Article
-
Mark
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
(
- Contribution to journal › Article
-
Mark
APOE -ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals
(
- Contribution to journal › Article
-
Mark
Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study
(
- Contribution to journal › Article
- 2022
-
Mark
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic : what is the role of stress perception, stress resilience, and β-amyloid?
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia : a meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease
(
- Contribution to journal › Article